stockrow
Saturday 7 November 2026
Export SLXN’s income statement to Excel — free account
Silexion Therapeutics Corp
SLXN Healthcare Biotechnology
- EPS
- +88.0%
- Free cash flow
- −16.6%
- Total debt
- −47.0%
Quarter to June 2026, against a year earlier
0.14
0.00
0.00%
Follow SLXN
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(771.23%) | 1,718.90% | (897.46%) | (17,021.95%) | |
| (125.80%) | (236.40%) | (200.00%) | (277.96%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(111.48%) | (305.12%) | (46,107.14%) | 6,492.09% | |
Free Cash Flow per Share |
(94.76) | (81.41) | (37.19) | (18.09) | |
Free Cash Flow |
(10.74) | (10.83) | (12.01) | (12.43) | |
Capital Expenditures |
(0.01) | (0.01) | — | — | |
| Other line items | |||||
Cash ROIC |
(60.36%) | (106.27%) | (439.84%) | (539.97%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(78.00) | (41.99) | (72.34) | 83.59 | |
Operating CF/Net income |
1.16 | 0.91 | 0.93 | 0.89 | |
Depreciation/Fixed assets |
(0.04) | 0.56 | 0.52 | 0.60 | |
Capex/Depreciation |
7.00 | (0.64) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(94.70) | (81.35) | (37.19) | (18.09) | |
Capex per Share |
(0.06) | (0.07) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 26 Oct 2026